Cite
Morgillo F, Fasano M, Della Corte CM, et al. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. ESMO Open. 2017;2(2):e000132doi: 10.1136/esmoopen-2016-000132.
Morgillo, F., Fasano, M., Della Corte, C. M., Sasso, F. C., Papaccio, F., Viscardi, G., Esposito, G., Di Liello, R., Normanno, N., Capuano, A., Berrino, L., Vicidomini, G., Fiorelli, A., Santini, M., & Ciardiello, F. (2017). Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. ESMO open, 2(2), e000132. https://doi.org/10.1136/esmoopen-2016-000132
Morgillo, Floriana, et al. "Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer." ESMO open vol. 2,2 (2017): e000132. doi: https://doi.org/10.1136/esmoopen-2016-000132
Morgillo F, Fasano M, Della Corte CM, Sasso FC, Papaccio F, Viscardi G, Esposito G, Di Liello R, Normanno N, Capuano A, Berrino L, Vicidomini G, Fiorelli A, Santini M, Ciardiello F. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. ESMO Open. 2017 May 02;2(2):e000132. doi: 10.1136/esmoopen-2016-000132. eCollection 2017. PMID: 28761738; PMCID: PMC5519802.
Copy
Download .nbib